Search Results
Oct 14, 2025, 06:05 ET Domino's Pizza® Announces Third Quarter 2025 Financial Results
$402.7 million in outstanding principal under the Company's 2018 7.5-year notes, (ii) prefund a portion of the interest payable on the 2025 Notes and (iii) capitalize $15.4 million for financing costs. Additionally, certain of the Company's subsidiaries also issued a new $320.0 million variable funding
More news about: Domino's Pizza, Inc.
Oct 14, 2025, 06:00 ET 歌禮與中國國家藥品監督管理局完成地尼法司他（ASC40）的新藥上市申請前溝通
在一項隨機、雙盲、安慰劑對照、多中心的 III 期臨床試驗中，地尼法司他（
More news about: 歌禮製藥有限公司
Oct 14, 2025, 06:00 ET Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
NCT05104125) and Phase III (NCT06192264) studies of denifanstat (ASC40) for the treatment of moderate-to-severe acne vulgaris. In the Phase III study, denifanstat
More news about: Ascletis Pharma Inc.
Oct 14, 2025, 06:00 ET Hyperscale Data Progresses Toward 100% Bitcoin Pairing as Digital Asset Treasury Climbs to $54 Million
position. "Our disciplined approach to the accumulation of Bitcoin is already proving fruitful," said Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "Short term volatility within the cryptocurrency and financial markets demonstrates the benefit
More news about: Hyperscale Data Inc.
Oct 14, 2025, 01:40 ET 2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China
In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease
More news about: RemeGen Co., Ltd
Oct 13, 2025, 22:45 ET Incorporação da GLAI e GIB pela GLA e consequente deslistagem do Nível 2
suspensivas: (i) lançamento, realização e liquidação da OPA Saída Nível 2; (ii) aprovação da Incorporação pelas assembleias da Companhia, GLA e GIB; (iii) ausência de mutações, flutuações e/ou atos, fatos ou eventos de força maior que afetem negativamente, de forma material, o patrimônio das Companhias,
More news about: GOL Linhas Aéreas Inteligentes S.A.
Oct 13, 2025, 22:37 ET Incorporation of GLAI and GIB into GLA and future delisting from Level 2
settlement of the Level 2 Exit Tender Offer; (ii) Approval of the Merger by the shareholders' meetings of the Company, GLA, and GIB; (iii) Absence of changes, fluctuations, or acts, facts, or force majeure events that materially and adversely affect the assets of the companies, occurring
More news about: GOL Linhas Aéreas Inteligentes S.A.
Oct 13, 2025, 20:00 ET Waters推出全新電荷檢測質譜技術，加速新一代生物治療藥物研發進程
所需樣品量僅為細胞與核酸現有其他分析方法的 1/100 。 [iii] 美國麻州米爾福德市2025年10月14日 /美通社/ -- Waters公司（紐約證券交易所代碼：WAT）今日隆重推出
More news about: Waters Corporation
Oct 13, 2025, 17:31 ET Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming 10 Years Amid Increasing Therapeutic Advancements | DelveInsight
planning a Phase III clinical trial (NCT05400811), which is not yet recruiting, to assess the efficacy and safety of this therapy for HDM-induced allergic asthma and rhinitis/rhino-conjunctivitis. Additionally, Immunotek has previously initiated another Phase III trial (NCT04435990)
More news about: DelveInsight Business Research, LLP
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Dow Inc. and Certain Officers - DOW
businesses organized into three operating segments: (i) Packaging & Specialty Plastics, (ii) Industrial Intermediates & Infrastructure, and (iii) Performance Materials & Coatings. Historically, Dow has touted its "industry-leading dividend," which is of particular importance
More news about: Pomerantz LLP
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times. On June 10, 2025, Unicycive
More news about: Pomerantz LLP
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action on Behalf of Investors in the Securities of Spirit Aviation Holdings, Inc. - FLYYQ
obligations; (ii) Spirit was also at substantial risk of being forced to file for Chapter 11 bankruptcy protection within a mere matter of months; (iii) accordingly, Defendants had overstated enhancements to Spirit's financial condition, liquidity, and overall business and operations, while simultaneously
More news about: Pomerantz LLP
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) the foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors;
More news about: Pomerantz LLP
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Cepton, Inc. and Certain Officers - CPTN
meaningfully explore the foregoing offer and failed to disclose its terms when recommending that Cepton's shareholders approve the Koito Acquisition; (iii) consequently, Cepton's shareholders were deprived of the opportunity to meaningfully consider whether to accept or reject the Koito Acquisition; and
More news about: Pomerantz LLP
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as
More news about: Pomerantz LLP
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Nutex Health Inc. and Certain Officers - NUTX
that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal
More news about: Pomerantz LLP
Oct 13, 2025, 14:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
On May 30, 2025, Summit issued a press release "announc[ing] topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab[.]" Although patients treated with ivonescimab and chemotherapy were 48% less likely to progress
More news about: Pomerantz LLP
Oct 13, 2025, 13:42 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Fortinet, Inc. of Class Action Lawsuit and Upcoming Deadlines - FTNT
upgrade; (ii) suggested customers had "excess [firewall] capacity from [purchasing firewalls in] prior years" and therefore did not need to upgrade; and (iii) revealed that the refresh could not have had "much business impact" as it consisted of only a "small percentage" of the Company's business, as the age
More news about: Pomerantz LLP
Oct 13, 2025, 11:00 ET Cardiovascular Drugs Market Size to Reach US$ 247.8 Billion by 2033, Driven by Rising Cardiovascular Disease Cases and Lifestyle Changes | According to DataM Intelligence
In August 2025, Roche and Alnylam (Nasdaq: ALNY) announced their decision to launch a Phase III cardiovascular outcomes trial (CVOT) to assess whether zilebesiran, an RNAi therapeutic, can reduce the risk of major adverse cardiovascular events in
More news about: DataM Intelligence 4 Market Research LLP
Oct 13, 2025, 10:17 ET Boehringer and Click Therapeutics present pivotal data for investigational prescription digital therapeutic CT-155 showing a statistically significant reduction in negative symptoms of schizophrenia
Oct. 13, 2025 /PRNewswire/ -- Boehringer Ingelheim and Click Therapeutics today shared data from the pivotal Phase III CONVOKE study (
More news about: Boehringer Ingelheim Pharmaceuticals, Inc.; Click Therapeutics
Oct 13, 2025, 09:30 ET McDaniel College Receives Approximately $15 Million Bequest, Largest Gift in the College's History
collaboration to develop the unique potential in every student. Represented by the Green Terror, over 20 athletic teams compete in the NCAA Division III Centennial Conference. A student-centered community of 1,600 undergraduates and 1,400 graduate students offers access to both Baltimore and Washington,
More news about: McDaniel College
Oct 13, 2025, 09:15 ET MOH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Molina Healthcare, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Healthcare's "medical cost trend assumptions"; (ii) that Molina Healthcare was experiencing a "dislocation between premium rates and medical cost trend"; (iii) that Molina Healthcare's near term growth was dependent on a lack of "utilization of behavioral health, pharmacy, and inpatient and outpatient services";
More news about: Robbins Geller Rudman & Dowd LLP
Oct 13, 2025, 09:00 ET NexPoint Launches Small Bay III DST Offering
offering materials, including NexPoint Small Bay III DST's Private Placement Memorandum ("PPM") dated October 10,2025, as amended or supplemented from time to time, including the "Risk Factors." An offer to sell interests ("Interests") in NexPoint Small Bay III DST (the "Parent Trust") may be made only pursuant
More news about: NexPoint
Oct 13, 2025, 09:00 ET iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data
maturation of the transplanted cells. Significant clinical efficacy was observed, including marked improvements in MDS-UPDRS Part III motor scores. In the low-dose cohort, UPDRS-III scores improved by an average of 30.6 points in the OFF state (a 52.82% improvement from baseline) and 12.9 points in the ON
More news about: iRegene therapeutics
Oct 13, 2025, 09:00 ET The Gross Law Firm Notifies Shareholders of Unicycive Therapeutics, Inc.(UNCY) of a Class Action Lawsuit and an Upcoming Deadline
manufacturing compliance requirements was overstated; (ii) the oxylanthanum carbonate new drug application's regulatory prospects were likewise overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times. DEADLINE:
More news about: Gross Law Firm